European Heart Journal Advance Access originally published online on June 2, 2006
European Heart Journal 2006 27(14):1754; doi:10.1093/eurheartj/ehl056
© The European Society of Cardiology 2006. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org
Aspirin and clopidogrel resistance: an emerging clinical entity
Bayer HealthCare
36 Columbia Road
PO Box 1910
Morristown
NJ 07962-1910
USA
E-mail address: tony.johns.b@bayer.com
Bayer HealthCare
36 Columbia Road
PO Box 1910
Morristown
NJ 07962-1910
USA
Bayer HealthCare
36 Columbia Road
PO Box 1910
Morristown
NJ 07962-1910
USA
| The first 10% of the full text of this article appears below. |
We read with interest the recent article which reviewed the issue of aspirin and clopidogrel resistance.1 The authors review the aspirin and clopidogrel clinical trial data and conclude that both therapies have emerged as efficacious in both the primary and